For senior professionals in biotech, a counteroffer is seldom a surprise. Experienced leaders are difficult to replace, and the departure of a head of CMC or a clinical development lead in the middle of a program creates real risk for the company. It is natural for an employer to try to keep you, and natural to feel the pull of being asked to stay.
That pull is worth examining before it arrives. The counteroffer conversation goes best when you have already done the thinking, and worst when you are doing it in real time across the table from someone you respect.
Start with why you were open to leaving
Before you resign, write down the reasons you engaged with the new opportunity in the first place. Be specific. "A better role" is not a reason. "I want to own the clinical development plan rather than execute someone else's" is.
Then sort those reasons into two groups: those a counteroffer could address and those it could not. Compensation, title, and sometimes scope can change quickly. The company's financing position, its pipeline priorities, the person you report to, and the way decisions get made usually cannot. If most of your reasons fall into the second group, a counteroffer may make staying more comfortable without making it better.
- Is the issue compensation, or is compensation standing in for something else, such as recognition, influence, or trust?
- If the company could offer this now, why did it not offer it before you resigned?
- Will the scope being offered still exist after the next financing, reorganization, or portfolio decision?
- How will your relationship with your CEO and peers change once they know you were prepared to leave?
What a counteroffer usually contains
Counteroffers in biotech typically combine some of the following: a higher base salary, a retention bonus, an additional equity grant, an expanded title, or a promise of broader responsibility. Each carries different weight.
A counteroffer can change what you are paid. It cannot easily change why you wanted to leave.
Cash and equity are concrete, but read the terms. Retention bonuses often carry repayment obligations if you leave within a set period, and new equity grants start a vesting clock that can hold you in place longer than you intended. Promises about future scope are the least concrete element of all. If expanded responsibility is part of the offer, ask that it be documented and that the timing be specific.
Notice the timing, too. A counteroffer assembled in two days tells you what the company can do under pressure. It tells you less about what it will do a year from now, when the pressure has passed and budgets have been reset.
It is also fair to weigh what the new opportunity offered that a counteroffer cannot: the stage of the company, the science, the leadership team, and the problem you would be solving. Those are often what made the new role compelling in the first place. A counteroffer can change what you are paid. It cannot easily change why you wanted to leave.
Resigning well, whatever you decide
Biotech is a small industry. The CEO you are leaving may later sit on a board you report to, and the hiring manager you disappoint may become a future partner. How you handle this moment will be remembered longer than the details of either offer.
If you have accepted a new role, resign in person where you can, with a short letter, and make clear that your decision is final. Express gratitude and offer a considered transition plan for your programs and your team. Declining to negotiate is not ungracious. It respects everyone's time, including that of the company you are joining.
If a counteroffer arrives anyway, listen, thank the person making it, and avoid negotiating in the room. You can acknowledge a sincere gesture without reopening a decision you have already made.
If you are genuinely undecided, settle that with yourself and with the new employer before you resign, not after. Using an outside offer purely as leverage carries a cost. Hiring managers, recruiters, and board members talk to one another, and a reputation for accepting offers you do not intend to keep can follow you into future searches.
There are situations where staying is the right call. A company may have genuinely misjudged your value, and a counteroffer may correct that while also addressing the underlying reason you looked. If so, accept it on clear, written terms. What matters is that the decision is yours, made deliberately, and not made for you by the momentum of a single conversation.
